Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.

Participated · Equity · Sep 2021

TailorMed provides a web-based financial assistance platform that matches patients to relevant opportunities across roughly 6,000 resources and streamlines ongoing program management. The company operates what it describes as the nation’s largest network of patients, providers, pharmacies, partners, and life science companies focused on affordability. Its platform is deployed across more than 1,000 sites of care, including Providence Health, UnityPoint Health, Yale-New Haven Health, and Advocate Aurora Health. TailorMed’s tools enable healthcare organizations to proactively identify, match, and enroll patients in financial assistance programs at scale, simplifying an operationally complex process. The product aims to improve the patient financial experience while reducing the cost of care delivery and increasing revenues for provider organizations. TailorMed is expanding and strengthening its network with support from strategic health-system investors. TailorMed offers a best-in-class financial navigation platform that automates identification of financially at-risk patients and matches/enrolls them in resources such as co-pay assistance, replacement drug programs, government subsidies, foundations, and programs addressing living expenses and social determinants of health. The platform is used by health systems, clinics, physician practices, specialty clinics and pharmacies nationwide and aims to reduce out-of-pocket responsibility and avoidance of care. For provider organizations, TailorMed shifts financial assistance from reactive downstream collections to proactive support at the point of care. The company says its technology supports patients across all medical conditions and treatment types. TailorMed will use the new funding to further expand its reach across health care and develop innovative financial solutions.

Participated · Series A · May 2021

Lydus Medical, based in Ra’anana, Israel, develops a novel product line to automate creation of small blood vessel anastomoses. Its lead product, the Vesseal, enables precise, symmetrical and rapid connection of blood and lymph vessels from 4.0 to 0.5mm for procedures including breast reconstruction, lymphedema treatment, bypass surgery and hemodialysis access. The company’s pipeline includes a diverse portfolio of products all based on a patented invention. Led by CEO Jessica Weiss, Lydus plans to use the funding to accelerate FDA clearance, scale product development and prepare for market entry. The company raised $2.7m in a Pre-A funding round.